Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The aberrant release of inflammatory mediators often referred to as a cytokine storm or cytokine release syndrome (CRS), is a common and sometimes fatal complication in acute infectious diseases including Ebola, dengue, COVID-19, and influenza. Fatal CRS occurrences have also plagued the development of highly promising cancer therapies based on T-cell engagers and chimeric antigen receptor (CAR) T cells. CRS is intimately linked with dysregulated and excessive cytokine release, including IFN-γ, TNF-α, IL 1, IL-6, and IL-10, resulting in a systemic inflammatory response leading to multiple organ failure. Here, we show that mice intravenously administered the agonistic hamster anti-mouse CD3ε monoclonal antibody 145-2C11 develop clinical and laboratory manifestations seen in patients afflicted with CRS, including body weight loss, hepatosplenomegaly, thrombocytopenia, increased vascular permeability, lung inflammation, and hypercytokinemia. Blood cytokine levels and gene expression analysis from lung, liver, and spleen demonstrated a hierarchy of inflammatory cytokine production and infiltrating immune cells with differentiating organ-dependent kinetics. IL-2, IFN-γ, TNF-α, and IL-6 up-regulation preceded clinical signs of CRS. The co-treatment of mice with a neutralizing anti-cytokine antibody cocktail transiently improved early clinical and laboratory features of CRS. We discuss the predictive use of this model in the context of new anti-cytokine strategies to treat human CRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, drug-induced cytokine release syndrome has been studies in a humanized mouse model with success measured by observing clinical signs and elevated human cytokines (IL-6, IFN-γ, TNF-α) that mirror human CRS (Ye et al., 2020; Nouveau et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Nouveau et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Cited by
Tvedt, T. H. A., Vo, A. K., Bruserud, Ø., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215190 · Cited by 68
Napodano, C., Carnazzo, V., Basile, V., Pocino, K., Stefanile, A., Gallucci, S., Natali, P., Basile, U., & Marino, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316556 · Cited by 41
“…cytokine storm or cytokine release syndrome are characterized by elevated levels of circulating cytokines, immune hyperactivation, and multi-organ disfunction that can come to be fatal [93]. ammatory cytokines, fi rst IL-6, then interferon-γ and IL-1, have been in many cytokine storms [94–99].”
BackgroundCheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors
Broni, E., Ashley, C. N., Adams, J., Manu, H., Aikins, E., Okom, M., Miller, W. A., Wilson, M. D., & Kwofie, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076298 · Cited by 29
Seckinger, A., Majocchi, S., Moine, V., Nouveau, L., Ngoc, H., Daubeuf, B., Ravn, U., Plèche, N., Calloud, S., Broyer, L., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01516-3 · Cited by 24
“IFNγ, IL-6, and TNFα were measured as previously described [40, 41].”
MethodSelf-citationZhang, Z., Li, Y., Shi, J., Zhu, L., Dai, Y., Fu, P., Liu, S., Hong, M., Zhang, J., Wang, J., et al. (2022) · Aging and Disease · doi:10.14336/ad.2022.1102 · Cited by 21
“In addition, siponimod and anti-CD3 Abs (145-2C11) can also affect systemic immune responses by causing a reduction in peripheral lymphocytes and change in blood inflammatory biomarkers in vivo [84, 125, 127].”
Background
Metadata
- Authors
- Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G.
- Affiliations
- Light Chain Bioscience (Switzerland) (CH)
- Light Chain Bioscience‐Novimmune S.A. Geneva Switzerland
- Corresponding author
- Ferlin, Walter G.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2021-05-19
- Volume
- 51
- Issue
- 8
- Pages
- 2074-2085
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- PMC
- PMC8237068
- OpenAlex
- W3157468375
- Cited by
- 25
- References
- 60
- Citations by year
- 2026: 8 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- cytokine release syndrome, CD3ε, interleukin-6, interferon-gamma, TNF-α, interleukin-2, cytokine storm, T-cell engagers, CAR T-cell therapy, systemic inflammatory response, lung inflammation, hepatosplenomegaly, thrombocytopenia, vascular permeability, cytokine gene expression
- MeSH terms
- Cytokine Release Syndrome, Animals, Antibodies, Antibodies, Monoclonal, Disease Models, Animal, Drug Therapy, Combination, Lymphocyte Activation, Phenotype, Severity of Illness Index, T-Lymphocytes, Cytokines, Treatment Outcome, CD3 Complex, Inflammation Mediators, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies. https://app.cochat.ai/papers/10.1002/eji.202149181
- The paper
- Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021). Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies. European Journal of Immunology. https://doi.org/10.1002/eji.202149181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.